A Phase 2 interventional study of Acalabrutinib (ACP-196) and Acalabrutinib (ACP-196) in Waldenström Macroglobulinemia (WM), sponsored by Acerta Pharma BV. Active, not recruiting at 38 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Waldenstrom Macroglobulinemia with a site in France — 11 open to participants now, 16 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · France.
Among the 41 studies in Waldenstrom Macroglobulinemia with a site in France, this one is the 23rd largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2014, is one of 12 in phase 2, reaches primary completion later than 0 of the 15 other live ones, and was the 17th registered.
524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.
Browse Waldenstrom Macroglobulinemia studies →11 of the 41 studies in Waldenstrom Macroglobulinemia with a site in France are open now. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in France, United States, Australia and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in France, United States, Australia and 9 more countries
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18+
Schrödinger, Inc. · Sites in France, United States, Italy and 5 more countries
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 9
First in 1995; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 39 across 429 interventional studies indexed under Waldenstrom Macroglobulinemia.
Median enrollment 130 across the 36 interventional studies, 136 across the 5 observational. Of the 21 that completed or were terminated, 7 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
AstraZeneca has 3 studies filed under Waldenstrom Macroglobulinemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Waldenstrom Macroglobulinemia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT05131022Nurix Therapeutics, Inc.A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | 2027-01 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT07101328Eli Lilly and CompanyA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | 2027-04 |
| NCT04893564Centre Hospitalier Universitaire, AmiensPrognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 41 studies in Waldenstrom Macroglobulinemia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
Clinical studies have shown that targeting the B-cell receptor (BCR) signaling pathway by inhibiting Bruton tyrosine kinase (BTK) produces significant clinical benefit in patients with non-Hodgkin lymphoma, including Waldenström macroglobulinemia (WM). Ibrutinib (IMBRUVICA®), an oral, small-molecule BTK inhibitor has been approved for the treatment for chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and WM.
Acerta Pharma BV (AcertaPharma) has developed a novel BTK inhibitor, acalabrutinib, that achieves significant oral bioavailability and potency in preclinical models.
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously untreated cohort only: A confirmed diagnosis of previously untreated WM in subjects who require treatment and do not want to receive chemoimmunotherapy or have comorbidities that would preclude chemoimmunotherapy such as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects previously treated with Waldenström Macroglobulinemia N=92
Drug: Acalabrutinib (ACP-196)
Subjects with treatment-naïve Waldenström Macroglobulinemia. N=14
Drug: Acalabrutinib (ACP-196)
Also known as: Acalabrutinib
Also known as: Acalabrutinib
Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria
ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.
Time frame: Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).
Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria
ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.
Time frame: Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).
Progression-free Survival (PFS) of Acalabrutinib by Investigator
Kaplan-Meier (K-M) estimates of the PFS assessments and its 95% confidence interval are provided using both modified 3rd and 6th IWWM criteria by investigator. K-M estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive or have not progressed by the given time over all patients at risk. Per 6th IWWM criteria, the progressive disease is defined as \>= 25% increase in serum IgM level with an absolute increase of at least 500 mg/dL from lowest nadir (requires confirmation on at least 2 consecutive measurements at least 4 weeks apart) and/or progression of clinical features attributable to the disease. Per modified 3rd IWWM criteria, besides IgM requirement as 6th criteria, it could also includes progression of clinically significant disease related symptoms and/or death from any cause or initiation of a new anti-neoplastic therapy.
Time frame: Up to approximately 3.8 years. Data cut at last subject have completed Cycle 27 (28 days per Cycle).
Overall Survival (OS) of Acalabrutinib by Investigator
Outcome Measure was pre-specified to summarize data per investigator assessment with respect to subject's vital/survival status is presented in the RRF and irrespective of iWWM 3rd or 6th criteria. Kaplan-Meier (K-M) estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive by the given time over all patients at risk.
Time frame: Primary analysis occur when all subjects have completed Cycle 27 or have discontinued before Cycle 27.
Summary of Duration of Response (DOR)
DOR is defined as the interval from the first documentation of Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR) or Minor Response (MR) to the earlier of the first documentation of definitive PD or death from any cause. The summary statistics are provided for DOR.
Time frame: Primary analysis occur when all subjects have completed Cycle 27 or have exit the study
In the original protocol, previously treated subjects were planned to be randomized 1:1 into 2 cohorts: Cohort 1 to receive Acala 100 mg BID for 28 days and Cohort 2 to receive Acala 200 mg once daily (QD) for 28 days. After enrollment started, the dose regimen was amended. The 200 mg QD dose was eliminated, and subjects who were enrolled under the original protocol and received treatment with 200 mg QD were switched to 100 mg BID.
| Milestone | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 |
|---|---|---|
| Started | 92 | 14 |
| 200 mg qd | 7 | 1 |
| 100 mg bid | 85 | 13 |
| Completed | 0 | 0 |
| Not completed | 92 | 14 |
| Withdrew: Death | 26 | 1 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Pi decision | 5 | 2 |
| Withdrew: Study terminated by sponsor | 54 | 8 |
ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.
| Participants | Previously Treated (N=92) | Treatment Naive (N=14) |
|---|---|---|
| ORR 6th IWWM criteria (CR+VGPR+PR+MR) | 87 | 13 |
| CR (6th IWWM criteria) | 4 | 0 |
| VGPR (6th IWWM criteria) | 21 | 0 |
| PR (6th IWWM criteria) | 52 | 10 |
| MR (6th) | 10 | 2 |
Kaplan-Meier (K-M) estimates of the PFS assessments and its 95% confidence interval are provided using both modified 3rd and 6th IWWM criteria by investigator. K-M estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive or have not progressed by the given time over all patients at risk. Per 6th IWWM criteria, the progressive disease is defined as \>= 25% increase in serum IgM level with an absolute increase of at least 500 mg/dL from lowest nadir (requires confirmation on at least 2 consecutive measurements at least 4 weeks apart) and/or progression of clinical features attributable to the disease. Per modified 3rd IWWM criteria, besides IgM requirement as 6th criteria, it could also includes progression of clinically significant disease related symptoms and/or death from any cause or initiation of a new anti-neoplastic therapy.
| percentage of subjects | Previously Treated (N=92) | Treatment Naive (N=14) |
|---|---|---|
| K-M Point Est. for PFS by 6th IWWM criteria | 81.9 (72.1 to 88.5) | 90.0 (47.3 to 98.5) |
| K-M Point Est. for PFS by 3rd IWWM criteria | 81.9 (72.1 to 88.5) | 90.0 (47.3 to 98.5) |
Outcome Measure was pre-specified to summarize data per investigator assessment with respect to subject's vital/survival status is presented in the RRF and irrespective of iWWM 3rd or 6th criteria. Kaplan-Meier (K-M) estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive by the given time over all patients at risk.
| Percentage of subjects | Previously Treated (N=92) | Treatment Naive (N=14) |
|---|---|---|
| Overall Survival (OS) of Acalabrutinib by Investigator | 89.0 (80.6 to 93.9) | 90.9 (50.8 to 98.7) |
DOR is defined as the interval from the first documentation of Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR) or Minor Response (MR) to the earlier of the first documentation of definitive PD or death from any cause. The summary statistics are provided for DOR.
| months | Previously Treated (N=92) | Treatment Naive (N=14) |
|---|---|---|
| DOR by Modified 3rd IWWM criteria | 21.9 ± 8.1 | 19.6 ± 8.41 |
| DOR by 6th IWWM Criteria | 21.7 ± 8.11 | 19.5 ± 8.45 |
ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.
| Participants | Previously Treated (N=92) | Treatment Naive (N=14) |
|---|---|---|
| ORR 3rd IWWM criteria (CR+VGPR+PR+MR) | 87 | 13 |
| CR (IWWM 3rd criteria) | 2 | 0 |
| VGPR (IWWM 3rd criteria) | 38 | 1 |
| PR (IWWM 3rd criteria) | 35 | 10 |
| MR (IWWM 3rd criteria) | 12 | 2 |
Collected over Reported Adverse Events (AEs) include events from the first dose of study drug until 30 days after the last dose of the study drug or start of a new anti-cancer therapy (whichever came first), assessed up to approximately 6 years and 7 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Previously Treated (PT) Cohort 1 | 26/87 (29.9%) | 56/87 (64.4%) | 87/87 (100%) |
| Previously Treated (PT) Cohort 2 | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| Previously Treated (PT) Total | 26/92 (28.3%) | 59/92 (64.1%) | 92/92 (100%) |
| Treatment Naive (TN) Cohort 1 | 1/13 (7.7%) | 9/13 (69.2%) | 13/13 (100%) |
| Treatment Naive (TN) Cohort 2 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Treatment Naive (TN) Total | 1/14 (7.1%) | 9/14 (64.3%) | 14/14 (100%) |
| Event | Previously Treated (PT) Cohort 1 | Previously Treated (PT) Cohort 2 | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 | Treatment Naive (TN) Cohort 2 | Treatment Naive (TN) Total |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 4/87 | 1/5 | 5/92 | 0/13 | 0/1 | 0/14 |
| CellulitisInfections and infestations | 3/87 | 1/5 | 4/92 | 0/13 | 0/1 | 0/14 |
| VasculitisVascular disorders | 0/87 | 1/5 | 1/92 | 0/13 | 0/1 | 0/14 |
| PneumoniaInfections and infestations | 11/87 | 0/5 | 11/92 | 0/13 | 0/1 | 0/14 |
| Lower respiratory tract infectionInfections and infestations | 10/87 | 0/5 | 10/92 | 0/13 | 0/1 | 0/14 |
| Cardiac failure congestiveCardiac disorders | 0/87 | 0/5 | 0/92 | 1/13 | 0/1 | 1/14 |
| Coronary artery diseaseCardiac disorders | 0/87 | 0/5 | 0/92 | 1/13 | 0/1 | 1/14 |
| Myocardial ischaemiaCardiac disorders | 0/87 | 0/5 | 0/92 | 1/13 | 0/1 | 1/14 |
| Urinary tract infectionInfections and infestations | 3/87 | 0/5 | 3/92 | 1/13 | 0/1 | 1/14 |
| FallInjury, poisoning and procedural complications | 2/87 | 0/5 | 2/92 | 1/13 | 0/1 | 1/14 |
| Event | Previously Treated (PT) Cohort 1 | Previously Treated (PT) Cohort 2 | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 | Treatment Naive (TN) Cohort 2 | Treatment Naive (TN) Total |
|---|---|---|---|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 5/87 | 1/5 | 6/92 | 0/13 | 1/1 | 1/14 |
| Abdominal pain upperGastrointestinal disorders | 6/87 | 0/5 | 6/92 | 1/13 | 1/1 | 2/14 |
| ConstipationGastrointestinal disorders | 22/87 | 1/5 | 23/92 | 3/13 | 1/1 | 4/14 |
| GastritisGastrointestinal disorders | 1/87 | 0/5 | 1/92 | 0/13 | 1/1 | 1/14 |
| NauseaGastrointestinal disorders | 19/87 | 2/5 | 21/92 | 4/13 | 1/1 | 5/14 |
| Influenza like illnessGeneral disorders | 4/87 | 2/5 | 6/92 | 2/13 | 1/1 | 3/14 |
| Upper respiratory tract infectionInfections and infestations | 24/87 | 3/5 | 27/92 | 3/13 | 1/1 | 4/14 |
| Alanine aminotransferase increasedInvestigations | 4/87 | 1/5 | 5/92 | 1/13 | 1/1 | 2/14 |
| Aspartate aminotransferase increasedInvestigations | 2/87 | 1/5 | 3/92 | 1/13 | 1/1 | 2/14 |
| Weight decreasedInvestigations | 6/87 | 0/5 | 6/92 | 0/13 | 1/1 | 1/14 |
| Age, Continuous(Years) | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 | Total |
|---|---|---|---|
| Mean | 68.7 ± 9.8 | 70.0 ± 13.0 | 68.9 ± 10.3 |
| Sex: Female, Male(Participants) | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 | Total |
|---|---|---|---|
| Female | 29 | 4 | 33 |
| Male | 63 | 10 | 73 |
| Ethnicity (NIH/OMB)(Participants) | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 80 | 14 | 94 |
| Unknown or Not Reported | 11 | 0 | 11 |
| Race (NIH/OMB)(Participants) | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 80 | 14 | 94 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 9 | 0 | 9 |
| Region of Enrollment(participants) | Previously Treated (PT) Total | Treatment Naive (TN) Cohort 1 | Total |
|---|---|---|---|
| USA | 19 | 9 | 28 |
| United Kingdom | 50 | 5 | 55 |
| Netherlands | 7 | 0 | 7 |
| Italy | 5 | 0 | 5 |
| Greece | 3 | 0 | 3 |
| France | 8 | 0 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2014 to primary completion in Oct 2019, 60 months.
Results were first posted in Apr 2020, 6 months after primary completion.
Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's 60 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Waldenstrom Macroglobulinemia →